{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:31:42Z","timestamp":1767857502891,"version":"3.49.0"},"reference-count":63,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1160,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Artificial Organs"],"published-print":{"date-parts":[[1998,11]]},"abstract":"<jats:p>Artificial cells are prepared in the laboratory for medical and biotechnological applications. Encapsulated cells are being studied for the treatment of diabetes, liver failure, and other conditions. More recently, there have been extensive studies into the use of encapsulated genetically engineered cells for gene therapy. We recently found that daily orally administered artificial cells, each containing a genetically engineered microorganism, can lower the elevated urea level in uremic rats to normal levels. This may solve the final obstacle of the lack of an effective oral urea removal system for the simple and inexpensive oral treatment of uremia. This is important because 85% of the world's uremic population cannot afford standard dialysis. Other areas of artificial cell application include use in hemoperfusion. Red blood cell substitutes based on modified hemoglobin are already in Phase 3 clinical trials in patients. Artificial cells containing enzymes are being developed for clinical trial in hereditary enzyme deficiency disease and other diseases. They are also being investigated for drug delivery and for use in other applications in biotechnology, chemical engineering, and medicine.<\/jats:p>","DOI":"10.1046\/j.1525-1594.1998.06243.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:06:09Z","timestamp":1047351969000},"page":"958-965","source":"Crossref","is-referenced-by-count":19,"title":["Artificial Cells with Emphasis on Cell Encapsulation of Genetically Engineered Cells"],"prefix":"10.1111","volume":"22","author":[{"given":"Thomas Ming Swi","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_9_2_2","unstructured":"KolffWJ.New ways of treating uraemia: The artificial kidney peritoneallavage intestinal lavage.Portman Square London: J & A Churchill 1947."},{"key":"e_1_2_9_3_2","first-page":"1","article-title":"Hemoglobin corpuscles.","volume":"16","author":"Chang TMS","year":"1988","journal-title":"J Biomater Artif Cells Artif Organs"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.146.3643.524"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1139\/y66-013"},{"key":"e_1_2_9_6_2","first-page":"13","article-title":"Semipermeable aqueous microcapsules (\u201cartificial cells\u201d):With emphasis on experiments in an extracorporeal shunt system.","volume":"12","author":"Chang TMS","year":"1966","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"e_1_2_9_7_2","unstructured":"ChangTMS.Artificial cells. Springfield Illinois: C.C. Thomas 1972."},{"key":"e_1_2_9_8_2","first-page":"S387","article-title":"Microencapsulated adsorbent hemoperfusion for uremia,intoxication and hepatic failure.","volume":"7","author":"Chang TMS","year":"1975","journal-title":"Kidney Int"},{"key":"e_1_2_9_9_2","doi-asserted-by":"crossref","unstructured":"WinchesterJF.Hemoperfusion.In: Maher JF ed.Replacement of renal function by dialysis.Boston: Kluwer Academic Publisher 1988:439\u2013592.","DOI":"10.1007\/978-94-009-1087-4_20"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6776628"},{"key":"e_1_2_9_11_2","first-page":"758","article-title":"An immunologic basis for the fibrotic reaction to implantedmicrocapsules.","volume":"23","author":"Soon\u2010Shiong P","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139888600900515"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/10731198909118855"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840120615"},{"key":"e_1_2_9_15_2","unstructured":"GoosenM ed.Fundamentals of animal cell encapsulation and immobilization.Boca Raton Florida: CRC Press 1992."},{"key":"e_1_2_9_16_2","unstructured":"ChangTMS.Artificial cells. In: Dulbecco R ed.Encyclopedia of human biology1997;1:457\u201363."},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1387-2656(08)70054-1"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-4310(97)80544-8"},{"key":"e_1_2_9_19_2","first-page":"1","article-title":"Bioartificial organs: Science, medicine and technology.","volume":"831","author":"Prokop A","year":"1977","journal-title":"Ann NY Acad Sci"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-4310(98)01246-5"},{"key":"e_1_2_9_21_2","first-page":"851","article-title":"Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymerencapsulated xenogenic cell line engineered to secrete hCNTF.","volume":"1","author":"Aebischer P","year":"1996","journal-title":"Hum Gene Ther"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/10731199609117437"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0963-6897(94)00072-R"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(96)00066-X"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1996.7.1-61"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199607290-00025"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.6.2324"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-696"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/10731199309117382"},{"key":"e_1_2_9_30_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/096368979500400413","article-title":"Implantable biohybrid artificial organs.","volume":"4","author":"Colton CK","year":"1996","journal-title":"Cell Transplant"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90399-6"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0896-883"},{"key":"e_1_2_9_33_2","unstructured":"ChangTMS&PrakashS.Artificial cells and genetically engineered microencapsulated forE. colicells for urea and ammonia removal. In: Tuar RS ed.Methods in molecular biology. Expression and Detection of RecombinantGene Series. Totowa New Jersey: Humana Press 1996:343\u201357."},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.260460615"},{"key":"e_1_2_9_35_2","first-page":"35","article-title":"Growth and survival of renal failure rats that received oralmicroencapsulated genetically engineeredE. coli DH5 cells for urea removal.","volume":"26","author":"Prakash S","year":"1998","journal-title":"Biomater Artif Cells Immobilization Biotechnol"},{"key":"e_1_2_9_36_2","unstructured":"WrongOM EdmondsCJ ChadwickVS.The large intestine.Lancaster: MTP Press 1981."},{"issue":"5138","key":"e_1_2_9_37_2","first-page":"242","article-title":"Semipermeable microcapsules containing catalasefor enzyme replacement in acatalsaemic mice.","volume":"218","author":"Chang TMS","year":"1968","journal-title":"Nature"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/229117a0"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(86)90281-3"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/10731199709118893"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90939-2"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197823173"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(71)80260-7"},{"key":"e_1_2_9_44_2","unstructured":"ChangTMS.Blood substitutes: Principles methods products and clinicaltrials. Vol. 1. Basel: Karger 1997."},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(75)90685-3"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005373-199708000-00019"},{"key":"e_1_2_9_47_2","unstructured":"GouldSA SehgalLR SehgalHL DeWoskinR MossGS.The clinical development of human polymerized hemoglobin. In: ChangTMS ed.Blood substitutes: Principles methods productsand clinical trials. Vol. 2. Basel: Karger 1998:12\u201328."},{"key":"e_1_2_9_48_2","unstructured":"PearceLB&GawrylMS.Overview of preclinical and clinical efficacy of Biopure'sHBOCs. In: Chang TMS ed.Blood substitutes: Principles methods products and clinical trials. Vol. 2. Basel: Karger 1998:82\u201398."},{"key":"e_1_2_9_49_2","first-page":"402","article-title":"o\u2010Raffinose polymerized hemoglobin as red blood cell substitute.","volume":"19","author":"Hsia JC","year":"1991","journal-title":"Biomater Artif Cells Immobilization Biotechnol"},{"key":"e_1_2_9_50_2","unstructured":"AdamsonJG&MooreC.Hemolink\u2122 an o\u2010raffinose crosslinked hemoglobin\u2010based oxygencarrier. In: Chang TMS ed.Blood substitutes: Principles methods products and clinical trials. Vol. 2. Basel: Karger 1998:62\u201379."},{"key":"e_1_2_9_51_2","first-page":"147","article-title":"The renal handling of hemoglobin.","volume":"81","author":"Bunn HF","year":"1968","journal-title":"Trans Assoc Am Physicians"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00587a001"},{"key":"e_1_2_9_53_2","unstructured":"NelsonDJ.Blood and HemAssist\u2122 (DCLHb): Potentially a complementary therapeuticteam. In: Chang TMS ed.Blood substitutes: Principles methods productsand clinical trials. Vol. 2. Basel: Karger 1998:39\u201357."},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.3109\/10731198809132573"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.3109\/10731198809132576"},{"key":"e_1_2_9_56_2","first-page":"407","article-title":"A Phase 1B safety evaluation of PEG hemoglobin as an adjuvant toradiation therapy in human cancer patients (Abstract).","volume":"24","author":"Shorr RG","year":"1996","journal-title":"Artif Cells Blood Substit Immobilization Biotechnol"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.21.8521"},{"key":"e_1_2_9_58_2","unstructured":"FreytagJW&TempletonD.Optro\u2122. In: Rudolph AS Rabinovici R Feuerstein GZ eds.Red cell substitutes: Basic principles and clinical application.New York: Marcel Dekker 1997:325\u201334."},{"key":"e_1_2_9_59_2","unstructured":"WinslowRM VandegriffM IntagliettaM eds.Blood substitutes. Boston: Birkh\u00e4user 1996."},{"key":"e_1_2_9_60_2","unstructured":"ChangTMS D'AgnilloF RazackS.A second generation hemoglobin based blood substitute with antioxidantactivities. In: Chang TMS ed.Blood substitutes: Principles methods products and clinical trials. Vol. 2. Basel: Karger 1998:178\u201386."},{"key":"e_1_2_9_61_2","first-page":"584","article-title":"Synthetic erythrocytes from lipid encapsulated hemoglobin.","volume":"8","author":"Djordjevich L","year":"1980","journal-title":"Exp Hematol"},{"key":"e_1_2_9_62_2","doi-asserted-by":"crossref","unstructured":"RudolphAS RabinoviciR FeuersteinGZ eds.Red blood cell substitutes. New York: Marcel Dekker 1997.","DOI":"10.1201\/9781482269796"},{"key":"e_1_2_9_63_2","unstructured":"TsuchidaEeds. Artificial red cells. New York: John Wiley & Sons 1995."},{"key":"e_1_2_9_64_2","unstructured":"ChangTMS&YuWP.Nanoencapsulation of hemoglobin and red blood cell enzymes based onnanotechnology and biodegradable polymer. In: Chang TMS ed.Blood substitutes:Principles methods productsand clinical trials. Vol. 2. Basel: Karger 1998:216\u201323."}],"container-title":["Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1525-1594.1998.06243.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1525-1594.1998.06243.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1525-1594.1998.06243.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1525-1594.1998.06243.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:57:54Z","timestamp":1694419074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1525-1594.1998.06243.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,11]]}},"alternative-id":["10.1046\/j.1525-1594.1998.06243.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1525-1594.1998.06243.x","archive":["Portico"],"relation":{},"ISSN":["0160-564X","1525-1594"],"issn-type":[{"value":"0160-564X","type":"print"},{"value":"1525-1594","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,11]]}}}